Charles G. Mullighan
Papers
1
Total Citations
2
H-Index
1
About
Dr. Charles G. Mullighan is a world-renowned hematopathologist and genomicist whose pioneering research has fundamentally reshaped our understanding of acute lymphoblastic leukemia (ALL). His work focuses on the genomic landscape and clonal evolution of high-risk ALL, particularly in pediatric populations. Dr. Mullighan’s major contributions include the discovery of novel genetic subtypes and therapeutic vulnerabilities in refractory leukemias. For instance, his landmark study on TCF3-HLF rearranged ALL—a rare but lethal subtype—revealed a distinct gene expression profile and demonstrated significant in vivo sensitivity to Aurora kinase inhibition, offering a new therapeutic avenue for patients with a historically dismal prognosis. With over 50,000 citations, his research has been instrumental in translating genomic discoveries into targeted therapies. Dr. Mullighan has received numerous accolades, including the ASH William Dameshek Prize and the St. Baldrick’s Foundation Robert J. Arceci Innovation Award, cementing his legacy as a transformative force in leukemia biology and precision oncology.
Research Focus
Key Achievements
Top Papers
- 1